Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vir Biotechnology, Inc.
Report date October 16, 2019 · Filed October 18, 2019
Section 16 reporting ended · disclosed 2019-10-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 362,844 |
Reported balance
After 2019-10-16 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-10-16 · Conversion · Acquired 218,400 · Balance 362,844 F1: Each share of the Issuer's Series A-2 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The shares are held in the name of the Klaus and Renate Frueh Revocable Trust Dated June 26, 2017. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2019-10-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-16 · Conversion · Disposed 218,400 · Balance 0 F1: Each share of the Issuer's Series A-2 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The shares are held in the name of the Klaus and Renate Frueh Revocable Trust Dated June 26, 2017. |
| Common StockSEC Table I · non-derivative | Direct | 77,777 |
Reported balance
Holding disclosure · report date 2019-10-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 77,777 |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Issuer's Series A-2 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2: The shares are held in the name of the Klaus and Renate Frueh Revocable Trust Dated June 26, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2019 Filed Oct 18, 2019 23:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 218,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053661 · doc4.xml · derivative · entry 3 Frueh Klaus · CIK 0001786308 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 218,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-2 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A-2 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A-2 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A-2 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held in the name of the Klaus and Renate Frueh Revocable Trust Dated June 26, 2017. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 218,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053661 · doc4.xml · nonDerivative · entry 1 Frueh Klaus · CIK 0001786308 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 362,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-2 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held in the name of the Klaus and Renate Frueh Revocable Trust Dated June 26, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.